J Rheumatol 2022 Jan 15. Epub 2022 Jan 15.
The German National Pediatric Rheumatologic Database was funded by the Federal Ministry for Research and Education (1999-2007), Deutsche Kinderrheuma-Stiftung, and pharmaceutical companies, namely AbbVie, Chugai, Novartis, Pfizer, and GSK. K. Baquet-Walscheid, MD, A. Heiligenhaus, MD, Department of Ophthalmology at St. Franziskus Hospital, Muenster, and University of Duisburg-Essen, Faculty of Medicine, Essen; K. Rothaus, MSc, Department of Ophthalmology at St. Franziskus Hospital, Muenster; M. Niewerth, MSc, German Rheumatism Research Center, a Leibniz Institute, Berlin; J. Klotsche, PhD, German Rheumatism Research Center, a Leibniz Institute, and Charité - University Medicine Berlin, Institute for Social Medicine, Epidemiology and Health Economics, Berlin; K. Minden, MD, German Rheumatism Research Center, a Leibniz Institute, and Charité - University Medicine Berlin, Department of Rheumatology and Clinical Immunology, Berlin, Germany. KBW has received honoraria from Novartis; KM has received honoraria from AbbVie, Medac, Pfizer, and Novartis. AH has received research grants from BMBF (FKZ, 01ER1504C), DFG (He 1877/19-1), Pfizer, and Novartis, and honoraria from AbbVie, Biermann, Allergan, Pfizer, Santen, and UCB. KR, MN, and JK declare no conflicts of interest relevant to this article. Address correspondence to Dr. K. Baquet-Walscheid, MD, FEBO, Department of Ophthalmology at St. Franziskus Hospital, Hohenzollernring 74, 48145 Muenster, Germany. Email: Accepted for publication December 14, 2021.
Objective: Data on uveitis in juvenile psoriatic arthritis ( JPsA), a category of juvenile idiopathic arthritis ( JIA), are scarce. We describe prevalence and risk factors for JPsA-associated uveitis ( JPsA-U).
Methods: Cross-sectional data from the German National Pediatric Rheumatological Database (2002-2014) were used to characterize JPsA-U and assess risk factors for the development of uveitis. Read More